TherapeuticsMD (TXMD) Shares Slide -0.13%

TherapeuticsMD (TXMD) : During the past 4 weeks, traders have been relatively bearish on TherapeuticsMD (TXMD), hence the stock is down -13.59% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.06% relative to the S&P 500. The 4-week change in the price of the stock is -10.69% and the stock has fallen -0.13% in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.48% and the 50-Day Moving Average is 7.45%. TherapeuticsMD, Inc. has dropped 5.82% during the last 3-month period . Year-to-Date the stock performance stands at -25.07%.


TherapeuticsMD (NYSEMKT:TXMD): stock turned positive on Friday. Though the stock opened at $7.68, the bulls momentum made the stock top out at $8.065 level for the day. The stock recorded a low of $7.68 and closed the trading day at $7.77, in the green by 0.52%. The total traded volume for the day was 1,023,010. The stock had closed at $7.73 in the previous days trading.

TherapeuticsMD, Inc. is a womens health care product company. The Company is engaged in creating and commercializing products for women. The Company is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins. It markets its prescription and OTC prenatal vitamins and other products under its vitaMedMD brand name and duplicate formulations of its prescription prenatal vitamin products, also referred to as generic formulations, under its BocaGreenMD brand name. The Companys products include prenatal vitamins, vitaMedMD Plus Rx, vitaMedMD One Rx, vitaMedMD RediChew Rx and BocaGreenMD Prena1 line of prescription prenatal vitamins, which included three prescription prenatal vitamins that were generic formulations of its vitaMedMD-branded prescription prenatal vitamins.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.